# SmartRent, Inc.: financial statements, quarterly

SMRT · NYSE · CIK 1837014 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/smrt.md) · [Financials](/companies/smrt/financials.md) · [Filings](/companies/smrt/filings.md) · [Insiders](/companies/smrt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/smrt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [58.1](/filings/0000950170-24-121840.md) | [60.3 d](/filings/0001193125-26-089953.md) | [50.5](/filings/0000950170-25-065034.md) | [48.5](/filings/0000950170-25-103553.md) | [40.5](/filings/0001193125-25-265821.md) | [35.4 d](/filings/0001193125-26-089953.md) | [41.3](/filings/0001193125-26-207630.md) | [38.3](/filings/0001193125-26-333924.md) | [36.2](/filings/0001193125-25-265821.md) | [36.5 d](/filings/0001193125-26-089953.md) | [38.7](/filings/0001193125-26-207630.md) | [39.8](/filings/0001193125-26-333924.md) |
| Cost of revenue | $m | [44.6](/filings/0000950170-24-121840.md) | [43.3 d](/filings/0001193125-26-089953.md) | [31.1](/filings/0000950170-25-065034.md) | [31.2](/filings/0000950170-25-103553.md) | [27.1](/filings/0001193125-25-265821.md) | [25.2 d](/filings/0001193125-26-089953.md) | [27.8](/filings/0001193125-26-207630.md) | [25.6](/filings/0001193125-26-333924.md) | [26.6](/filings/0001193125-25-265821.md) | [22.4 d](/filings/0001193125-26-089953.md) | [23.6](/filings/0001193125-26-207630.md) | [23.6](/filings/0001193125-26-333924.md) |
| Research and development | $m | [7.6](/filings/0000950170-24-121840.md) | [7.5 d](/filings/0001193125-26-089953.md) | [8.4](/filings/0000950170-25-065034.md) | [7.5](/filings/0000950170-25-103553.md) | [6.6](/filings/0001193125-25-265821.md) | [6.9 d](/filings/0001193125-26-089953.md) | [8.3](/filings/0001193125-26-207630.md) | [6.5](/filings/0001193125-26-333924.md) | [6.1](/filings/0001193125-25-265821.md) | [5.4 d](/filings/0001193125-26-089953.md) | [6.1](/filings/0001193125-26-207630.md) | [5.6](/filings/0001193125-26-333924.md) |
| Operating income | $m | [(9.9)](/filings/0000950170-24-121840.md) | [(5.8) d](/filings/0001193125-26-089953.md) | [(10.2)](/filings/0000950170-25-065034.md) | [(6.9)](/filings/0000950170-25-103553.md) | [(11.7)](/filings/0001193125-25-265821.md) | [(13.0) d](/filings/0001193125-26-089953.md) | [(41.3)](/filings/0001193125-26-207630.md) | [(11.7)](/filings/0001193125-26-333924.md) | [(7.0)](/filings/0001193125-25-265821.md) | [(4.0) d](/filings/0001193125-26-089953.md) | [(5.1)](/filings/0001193125-26-207630.md) | [(6.5)](/filings/0001193125-26-333924.md) |
| Income tax | $m | [(0.0)](/filings/0000950170-24-121840.md) | [(0.1) d](/filings/0001193125-26-089953.md) | [0.0](/filings/0000950170-25-065034.md) | [0.1](/filings/0000950170-25-103553.md) | [0.0](/filings/0001193125-25-265821.md) | [0.1 d](/filings/0001193125-26-089953.md) | [0.1](/filings/0001193125-26-207630.md) | [(0.0)](/filings/0001193125-26-333924.md) | [0.1](/filings/0001193125-25-265821.md) | [(0.1) d](/filings/0001193125-26-089953.md) | [0.0](/filings/0001193125-26-207630.md) | [(0.2)](/filings/0001193125-26-333924.md) |
| Net income | $m | [(7.7)](/filings/0000950170-24-121840.md) | [(3.3) d](/filings/0001193125-26-089953.md) | [(7.7)](/filings/0001193125-25-265821.md) | [(4.6)](/filings/0001193125-25-265821.md) | [(9.9)](/filings/0001193125-25-265821.md) | [(11.4) d](/filings/0001193125-26-089953.md) | [(40.2)](/filings/0001193125-26-333924.md) | [(10.9)](/filings/0001193125-26-333924.md) | [(6.3)](/filings/0001193125-25-265821.md) | [(3.2) d](/filings/0001193125-26-089953.md) | [(4.4)](/filings/0001193125-26-333924.md) | [(5.6)](/filings/0001193125-26-333924.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0000950170-24-121840.md) | not reported | [(0.04)](/filings/0000950170-25-065034.md) | [(0.02)](/filings/0000950170-25-103553.md) | [(0.05)](/filings/0001193125-25-265821.md) | not reported | [(0.21)](/filings/0001193125-26-207630.md) | [(0.06)](/filings/0001193125-26-333924.md) | [(0.03)](/filings/0001193125-25-265821.md) | not reported | [(0.02)](/filings/0001193125-26-207630.md) | [(0.03)](/filings/0001193125-26-333924.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0000950170-24-121840.md) | not reported | [(0.04)](/filings/0000950170-25-065034.md) | [(0.02)](/filings/0000950170-25-103553.md) | [(0.05)](/filings/0001193125-25-265821.md) | not reported | [(0.21)](/filings/0001193125-26-207630.md) | [(0.06)](/filings/0001193125-26-333924.md) | [(0.03)](/filings/0001193125-25-265821.md) | not reported | [(0.02)](/filings/0001193125-26-207630.md) | [(0.03)](/filings/0001193125-26-333924.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [211](/filings/0000950170-24-121840.md) | [215](/filings/0001193125-26-089953.md) | [205](/filings/0000950170-25-065034.md) | [187](/filings/0000950170-25-103553.md) | [163](/filings/0001193125-25-265821.md) | [142](/filings/0001193125-26-089953.md) | [126](/filings/0001193125-26-207630.md) | [105](/filings/0001193125-26-333924.md) | [100](/filings/0001193125-25-265821.md) | [105](/filings/0001193125-26-333924.md) | [98.8](/filings/0001193125-26-207630.md) | [92.7](/filings/0001193125-26-333924.md) |
| Current assets | $m | [344](/filings/0000950170-23-059762.md) | [340](/filings/0000950170-25-033086.md) | [319](/filings/0000950170-24-055086.md) | [314](/filings/0000950170-24-092293.md) | [285](/filings/0000950170-24-121840.md) | [258](/filings/0001193125-26-089953.md) | [228](/filings/0000950170-25-065034.md) | [218](/filings/0000950170-25-103553.md) | [201](/filings/0001193125-25-265821.md) | [188](/filings/0001193125-26-333924.md) | [169](/filings/0001193125-26-207630.md) | [162](/filings/0001193125-26-333924.md) |
| Total assets | $m | [516](/filings/0000950170-23-059762.md) | [510](/filings/0000950170-25-033086.md) | [485](/filings/0000950170-24-055086.md) | [475](/filings/0000950170-24-092293.md) | [449](/filings/0000950170-24-121840.md) | [420](/filings/0001193125-26-089953.md) | [366](/filings/0000950170-25-065034.md) | [354](/filings/0000950170-25-103553.md) | [336](/filings/0001193125-25-265821.md) | [321](/filings/0001193125-26-333924.md) | [300](/filings/0001193125-26-207630.md) | [294](/filings/0001193125-26-333924.md) |
| Current liabilities | $m | [124](/filings/0000950170-23-059762.md) | [117](/filings/0000950170-25-033086.md) | [107](/filings/0000950170-24-055086.md) | [100](/filings/0000950170-24-092293.md) | [86.0](/filings/0000950170-24-121840.md) | [71.0](/filings/0001193125-26-089953.md) | [75.9](/filings/0000950170-25-065034.md) | [80.1](/filings/0000950170-25-103553.md) | [72.6](/filings/0001193125-25-265821.md) | [60.0](/filings/0001193125-26-333924.md) | [42.7](/filings/0001193125-26-207630.md) | [42.7](/filings/0001193125-26-333924.md) |
| Total liabilities | $m | [172](/filings/0000950170-23-059762.md) | [167](/filings/0000950170-25-033086.md) | [152](/filings/0000950170-24-055086.md) | [146](/filings/0000950170-24-092293.md) | [143](/filings/0000950170-24-121840.md) | [131](/filings/0001193125-26-089953.md) | [115](/filings/0000950170-25-065034.md) | [115](/filings/0000950170-25-103553.md) | [101](/filings/0001193125-25-265821.md) | [88.8](/filings/0001193125-26-333924.md) | [69.6](/filings/0001193125-26-207630.md) | [68.6](/filings/0001193125-26-333924.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [343](/filings/0000950170-24-121840.md) | [342](/filings/0001193125-26-089953.md) | [333](/filings/0001193125-25-265821.md) | [329](/filings/0001193125-25-265821.md) | [305](/filings/0001193125-25-265821.md) | [289](/filings/0001193125-26-333924.md) | [251](/filings/0001193125-26-333924.md) | [239](/filings/0001193125-26-333924.md) | [234](/filings/0001193125-25-265821.md) | [232](/filings/0001193125-26-333924.md) | [231](/filings/0001193125-26-333924.md) | [225](/filings/0001193125-26-333924.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [14.3 d](/filings/0000950170-24-121840.md) | [7.3 d](/filings/0001193125-26-089953.md) | [(3.3)](/filings/0000950170-25-065034.md) | [(13.9) d](/filings/0000950170-25-103553.md) | [(3.7) d](/filings/0001193125-25-265821.md) | [(12.0) d](/filings/0001193125-26-089953.md) | [(12.2)](/filings/0001193125-26-207630.md) | [(14.9) d](/filings/0001193125-26-333924.md) | [(2.1) d](/filings/0001193125-25-265821.md) | [7.7 d](/filings/0001193125-26-089953.md) | [(4.5)](/filings/0001193125-26-207630.md) | [(1.7) d](/filings/0001193125-26-333924.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-121840.md) | [0.0 d](/filings/0001193125-26-089953.md) | [0.0](/filings/0000950170-25-065034.md) | [0.2 d](/filings/0000950170-25-103553.md) | [0.2 d](/filings/0001193125-25-265821.md) | [1.2 d](/filings/0001193125-26-089953.md) | [2.2](/filings/0001193125-26-207630.md) | [1.3 d](/filings/0001193125-26-333924.md) | [0.1 d](/filings/0001193125-25-265821.md) | [0.0 d](/filings/0001193125-26-089953.md) | [0.0](/filings/0001193125-26-207630.md) | [0.2 d](/filings/0001193125-26-333924.md) |
| Share repurchases | $m | not reported | not reported | [4.4](/filings/0000950170-25-065034.md) | [2.0 d](/filings/0000950170-25-103553.md) | [17.1 d](/filings/0001193125-25-265821.md) | [5.1 d](/filings/0001193125-26-089953.md) | [1.2](/filings/0001193125-26-207630.md) | [3.7 d](/filings/0001193125-26-333924.md) | [0.0 d](/filings/0001193125-25-265821.md) | [(0.0) d](/filings/0001193125-26-089953.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [196](/filings/0000950170-23-059762.md) | [198](/filings/0000950170-24-055086.md) | [200](/filings/0000950170-24-092293.md) | [202](/filings/0000950170-24-121840.md) | [203](/filings/0000950170-25-065034.md) | [202](/filings/0000950170-25-103553.md) | [199](/filings/0001193125-25-265821.md) | [192](/filings/0001193125-26-207630.md) | [189](/filings/0001193125-26-333924.md) | [188](/filings/0001193125-25-265821.md) | [192](/filings/0001193125-26-207630.md) | [192](/filings/0001193125-26-333924.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 191,611,799 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333924.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.